Ventyx Biosciences Reports Clinical Data for its NLRP3

Ventyx Biosciences Announces Positive Results from the Phase 2 ...

VTX002 60 mg achieved the primary endpoint of clinical remission with a high rate of complete endoscopic remission.

Ventyx Biosciences to Report Fourth Quarter and Full Year 2022 ...

... Results on March 23, 2023. March 15, 2023 ... Our current pipeline includes three internally discovered clinical programs targeting TYK2, S1P1R and NLRP3 ...

united states securities and exchange commission - form 8-k

Ventyx Biosciences Reports First Quarter 2022 Financial Results and Highlights Recent Corporate Progress. Topline Phase 1 data for our ...

Ventyx Biosciences to Report Topline Results from the Phase 1 trial ...

Our current pipeline includes three clinical-stage programs targeting TYK2, S1P1R and NLRP3, positioning us to become a leader in the ...

Ventyx Biosciences Announces $27 Million Strategic Investment ...

Data from both trials are expected in 2025. About ... Our current pipeline includes internally discovered clinical programs targeting NLRP3 ...

8-K | iXBRL Viewer - Ventyx Biosciences, Inc.

Our current pipeline includes three clinical-stage internally discovered programs targeting TYK2, S1P1R and NLRP3, positioning us to become a leader in the ...

Ventyx Biosciences Announces Results from the Phase 2 Trial of ...

... patient reported outcome) from baseline to Week 12. ... Our current pipeline includes internally discovered clinical programs targeting NLRP3 ...

Ventyx Biosciences Presents New 52-Week Results from the Phase ...

Our current pipeline includes internally discovered clinical programs targeting NLRP3 ... Report on Form 10-Q for the quarter ended June 30 ...

Corporate Presentation - Ventyx Biosciences, Inc.

Grand View Research Parkinson's disease market report; 2. ClearView Healthcare Partners market research for internal use. Page 19. 19. NLRP3 Is ...

Form 8-K for Ventyx Biosciences INC filed 08/08/2024

“We are looking forward to advancing our portfolio of NLRP3 inhibitors into three Phase 2 clinical trials in the coming months with clinical updates.

ventyx biosciences, inc.

... our TYK2 inhibitor VTX958, our S1P1R modulator VTX002 and our peripheral NLRP3 inhibitor VTX2735. We plan to initiate Phase 2 trials of VTX958 in psoriasis ...

Ventyx Biosciences, Inc.

(the “Company”), issued a press release announcing preclinical data regarding its CNS-penetrant NLRP3 inhibitor, VTX3232, in murine diet-induced ...

0000950170-23-021222 | 8-K | iXBRL Viewer | Ventyx Biosciences ...

Ventyx Biosciences Reports First Quarter 2023 ... Our current pipeline includes internally discovered clinical programs targeting TYK2, S1P1R and NLRP3 ...

Form 424B3 for Ventyx Biosciences INC filed 11/15/2024

... our Annual Report on Form 10-K and our Quarterly Reports on ... our development activities and current and future clinical trials, including study.

Ventyx Biosciences Announces Positive Preclinical Data for CNS ...

... medical need, today announced positive preclinical data for its CNS-penetrant NLRP3 inhibitor VTX3232 in murine diet-induced obesity models.

Form 8-K for Ventyx Biosciences INC filed 06/05/2024

(the “Company”), issued a press release announcing preclinical data regarding its CNS-penetrant NLRP3 ... includes internally discovered clinical ...

ventyx biosciences, inc.

Ventyx will host a virtual investor event on March 11, 2024, to provide key clinical updates on our NLRP3 portfolio, including topline results ...

Ventyx Biosciences Announces Appointment of William Sandborn ...

Dr. Sandborn brings a wealth of clinical experience and knowledge to Ventyx as we advance our clinical-stage pipeline of novel oral therapies for patients with ...

Annual Report - Ventyx Biosciences, Inc.

Based on both animal model studies and clinical data, NLRP3 has been shown to be associated with a diverse range of diseases and conditions, including ...

ventyx biosciences, inc.

... report to be signed on its behalf by the undersigned hereunto duly ... We continue to believe that data from our Phase 2 study with our ...